Biopharmaceuticals – A Global Market Overview
Biopharmaceuticals, or biologics, are drugs derived from living organisms such as bacteria, yeast, or mammalian cells, using advanced biotechnology methods like recombinant DNA technology. These drugs are typically large and complex molecules, including proteins, nucleic acids, and vaccines, in contrast to traditional small-molecule drugs. Biopharmaceutical products are developed to address chronic, complex, and rare illnesses, providing targeted treatments that conventional drugs often lack. They are used in therapeutic areas such as oncology, autoimmune diseases, diabetes, inflammatory and infectious diseases, neurological conditions, cardiovascular diseases, and blood disorders. Key products include monoclonal antibodies for cancer and autoimmune disorder treatments, erythropoietin (EPO) for anemia management, recombinant insulin for diabetes, G-CSF to enhance white blood cell production, interferons for viral infection treatment, and human growth hormones (HGH) for growth deficiencies. These therapies deliver solutions like gene and enzyme replacements. Biopharmaceuticals offer targeted, precise treatments, providing innovative solutions for complex medical needs, and continue to play a vital role in modern medicine. The global Biopharmaceuticals market is estimated at $412.1 billion in 2024 and is projected to grow to $698.7 billion by 2030, with a CAGR of 9.2% during the forecast period 2024-2030.
The biopharmaceutical market is fueled by the rising incidence of chronic illnesses, such as cancer, diabetes, heart disease, and autoimmune conditions, which need prolonged treatment. Governments worldwide are enhancing awareness and implementing strategies to promote the use of biopharmaceuticals, particularly for chronic, rare, and genetic diseases. There is an increasing demand for specialized therapies, such as monoclonal antibodies and gene treatments, along with a rise in regulatory approvals and a strong pipeline of products. Technological advancements like CRISPR gene editing and next-generation sequencing are also fueling innovation, allowing for more effective care. Furthermore, rising healthcare expenditure and investments in research and development, especially in developing nations, are driving market expansion. This increasing demand for innovative therapies is expected to continue driving the growth of the biopharmaceutical market during the forecast period.
Biopharmaceuticals Regional Market Analysis
North America dominates the global biopharmaceutical market, accounting for an estimated market share of 40.6% in 2024 due to technological advancements, increased investment in research and development, and greater awareness of disease diagnosis and treatment. The focus of the United States government on creating advanced medicines and approving new therapeutics further boosts the market. Additionally, this region benefits from robust reimbursement options, which facilitate the adoption of innovative therapies. On the other hand, the Asia-Pacific region is expected to witness the fastest growth with a CAGR of 11.2% during the forecast period 2024-2030, driven by the rising prevalence of chronic diseases, increased healthcare spending, and government investments in healthcare infrastructure. The rising awareness of biological drugs, the leadership of contract manufacturing organizations, and the growing dominance of emerging countries like China and India in vaccine production and drug manufacturing are key factors driving the expansion of the market.
Biopharmaceuticals Market Analysis by Product
The biopharmaceuticals sector is segmented by product into monoclonal antibodies (moAb), biotech vaccines, recombinant human insulin, erythropoietin, G-CSF, interferons, human growth hormones, and others. The monoclonal antibodies segment represents the largest market, comprising 35.2% in 2024, and is also the fastest-growing segment, with an anticipated CAGR of 11% during the forecast period from 2024 to 2030. Their growth is propelled by their effectiveness in treatment and their use in managing chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. The increasing acceptance of monoclonal antibodies is driven by their ability to specifically target disease cells, reducing side effects, and their growing use in cancer treatments, especially in developed countries. Furthermore, the surge in cancer and autoimmune disorders is boosting demand for these products. Biotech vaccines, the second-largest segment, are experiencing growth due to the increased demand for vaccinations resulting from new disease outbreaks like COVID-19 and seasonal influenza, along with ongoing vaccination initiatives. These elements, combined with a boost in pharmaceutical research and development and global healthcare expenditures, are anticipated to sustain growth in both the monoclonal antibodies and vaccine sectors throughout the forecast period.
Biopharmaceuticals Market Analysis by Application
The biopharmaceuticals market is segmented by application into oncology, autoimmune disorders, diabetes, inflammatory and infectious diseases, neurological diseases, cardiovascular diseases (CVD), and others. Among these, the oncology segment leads the market with a share of 36.9% in 2024 and is projected to record the fastest CAGR of 10.6% from 2024 to 2030. This growth is driven by the increasing incidence of cancer, heightened awareness, and the growing demand for biopharmaceutical treatments for cancers such as lung, breast, and colorectal. The rapid advancements in cancer research and the approval of new treatments, including targeted therapies and immunotherapies, contribute significantly to the expansion of this segment. Biopharmaceutical companies are investing in cancer research, concentrating on innovative therapies like antibody-drug conjugates and cell therapies. Furthermore, the cardiovascular disease segment is also anticipated to experience significant growth due to the increasing prevalence of heart disease, especially among older adults, and the ongoing development of biologic treatments such as monoclonal antibodies and gene therapies.
Biopharmaceuticals Market Report Scope
This global report on Biopharmaceuticals analyzes the global and regional markets based on product, and application for the period 2021-2030 with projections from 2024 to 2030 in terms of value in US$. In addition to providing profiles of major companies operating in this space, the latest corporate and industrial developments have been covered to offer a clear panorama of how and where the market is progressing.
Key Metrics
Historical Period: 2021-2023
Base Year: 2024
Forecast Period: 2024-2030
Units: Value market in US$
Companies Mentioned: 20+
Biopharmaceuticals Market by Geographic Region
- North America (The United States, Canada, and Mexico)
- Europe (Germany, France, the United Kingdom, Italy, Spain, and Rest of Europe)
- Asia-Pacific (Japan, China, India, South Korea, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, and Rest of South America)
- Rest of World
- Monoclonal Antibodies (moAb)
- Biotech Vaccines
- Recombinant Human (RH) Insulin
- Erythropoietin
- Granulocyte Colony-Stimulating Factor (G-CSF)
- Interferons
- Human Growth Hormones (HGH)
- Other Biopharmaceuticals (including Blood Factors, Thrombolytic Agents, Interleukins, Tumor Necrosis Factor, and Therapeutic Enzymes)
- Oncology
- Autoimmune Disorders???
- Diabetes
- Inflammatory and Infectious Diseases
- Neurological Diseases
- Cardiovascular Diseases
- Others (Including Metabolic Disorders, Blood Disorders and Others)
1. INTRODUCTION
Product Outline
Biopharmaceuticals Defined
Biopharmaceuticals Products
Monoclonal Antibodies (moAb)
Biotech Vaccines
Recombinant Human (RH) Insulin
Erythropoietin
Granulocyte Colony-Stimulating Factor (G-CSF)
Interferons
Human Growth Hormones (HGH)
Other Biopharmaceuticals (Including Blood Factors, Thrombolytic Agents, Interleukins, Tumor Necrosis Factor, and Therapeutic Enzymes)
Biopharmaceuticals Applications
Oncology
Autoimmune Disorders
Diabetes
Inflammatory and Infectious Diseases
Neurological Diseases
Cardiovascular Diseases
Others (Including Metabolic Disorders, Blood Disorders and Others)
2. Key Market Trends
3. Key Global Players
AbbVie Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Biocon Ltd.
Biogen Inc.
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Eli Lilly and Company
F. Hoffmann-La Roche AG
GSK plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Novo Nordisk A/S
Pfizer Inc
Regeneron Pharmaceuticals, Inc.
Sanofi S.A
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
UCB S.A.
4. Key Business & Product Trends
5. Global Market Overview
Global Biopharmaceuticals Market Overview by Product
Biopharmaceuticals Product Market Overview by Global Region
Monoclonal Antibodies (moAb)
Biotech Vaccines
Recombinant Human (RH) Insulin
Erythropoietin
Granulocyte Colony-Stimulating Factor (G-CSF)
Interferons
Human Growth Hormones (HGH)
Other Biopharmaceuticals
Global Biopharmaceuticals Market Overview by Application
Biopharmaceuticals Application Market Overview by Global Region
Oncology
Autoimmune Disorders
Diabetes
Inflammatory and Infectious Diseases
Neurological Diseases
Cardiovascular Diseases
Others
PART B: REGIONAL MARKET PERSPECTIVE
Global Biopharmaceuticals Market Overview by Geographic Region
REGIONAL MARKET OVERVIEW
6. North America
North American Biopharmaceuticals Market Overview by Geographic Region
North American Biopharmaceuticals Market Overview by Product
North American Biopharmaceuticals Market Overview by Application
Country-wise Analysis of North American Biopharmaceuticals Market
The United States
United States Biopharmaceuticals Market Overview by Product
United States Biopharmaceuticals Market Overview by Application
Canada
Canadian Biopharmaceuticals Market Overview by Product
Canadian Biopharmaceuticals Market Overview by Application
Mexico
Mexican Biopharmaceuticals Market Overview by Product
Mexican Biopharmaceuticals Market Overview by Application
7. Europe
European Biopharmaceuticals Market Overview by Geographic Region
European Biopharmaceuticals Market Overview by Product
European Biopharmaceuticals Market Overview by Application
Country-wise Analysis of European Biopharmaceuticals Market
Germany
German Biopharmaceuticals Market Overview by Product
German Biopharmaceuticals Market Overview by Application
France
French Biopharmaceuticals Market Overview by Product
French Biopharmaceuticals Market Overview by Application
The United Kingdom
United Kingdom Biopharmaceuticals Market Overview by Product
United Kingdom Biopharmaceuticals Market Overview by Application
Italy
Italian Biopharmaceuticals Market Overview by Product
Italian Biopharmaceuticals Market Overview by Application
Spain
Spanish Biopharmaceuticals Market Overview by Product
Spanish Biopharmaceuticals Market Overview by Application
Rest of Europe
Rest of Europe Biopharmaceuticals Market Overview by Product
Rest of Europe Biopharmaceuticals Market Overview by Application
8. Asia-Pacific
Asia-Pacific Biopharmaceuticals Market Overview by Geographic Region
Asia-Pacific Biopharmaceuticals Market Overview by Product
Asia-Pacific Biopharmaceuticals Market Overview by Application
Country-wise Analysis of Asia-Pacific Biopharmaceuticals Market
Japan
Japanese Biopharmaceuticals Market Overview by Product
Japanese Biopharmaceuticals Market Overview by Application
China
Chinese Biopharmaceuticals Market Overview by Product
Chinese Biopharmaceuticals Market Overview by Application
India
Indian Biopharmaceuticals Market Overview by Product
Indian Biopharmaceuticals Market Overview by Application
South Korea
South Korean Biopharmaceuticals Market Overview by Product
South Korean Biopharmaceuticals Market Overview by Application
Rest of Asia-Pacific
Rest of Asia-Pacific Biopharmaceuticals Market Overview by Product
Rest of Asia-Pacific Biopharmaceuticals Market Overview by Application
9. South America
South American Biopharmaceuticals Market Overview by Geographic Region
South American Biopharmaceuticals Market Overview by Product
South American Biopharmaceuticals Market Overview by Application
Country-wise Analysis of South American Biopharmaceuticals Market
Brazil
Brazilian Biopharmaceuticals Market Overview by Product
Brazilian Biopharmaceuticals Market Overview by Application
Argentina
Argentine Biopharmaceuticals Market Overview by Product
Argentine Biopharmaceuticals Market Overview by Application
Rest of South America
Rest of South American Biopharmaceuticals Market Overview by Product
Rest of South American Biopharmaceuticals Market Overview by Application
10. Rest of World
Rest of World Biopharmaceuticals Market Overview by Product
Rest of World Biopharmaceuticals Market Overview by Application
PART C: GUIDE TO THE INDUSTRY
PART D: ANNEXURE
1. RESEARCH METHODOLOGY
2. FEEDBACK
Key Market Trends
The global economic downturn of the recent past has left the biopharmaceutical industry practically unscathed, with contractions and losses being negligible, thereby indicating that the industry is well on the track for full recovery and growth. Though the global economy is limping back to normalcy, the biopharmaceutical industry has remained dynamic and growing, with survey results indicating companies spending and investing greater amounts on R&D and bioprocessing capacities. The larger and well-entrenched companies have been adopting aggressive strategies aimed at cutting costs and enhancing efficiency, a trend which has proven to be of immense benefit to contract manufacturing and research organizations (CMOs and CROs). Though the earlier inclination towards cutting staff and divesting facilities has been on the decline, this could very well be a reflection of attaining limits of eliminating in-house expertise and facilities. A few of the major biopharmaceutical industry trends are enumerated as under.
Completion of Inspiration's Hemophilia Products Sale
Inspiration Biopharmaceuticals and Ipsen have completed the sale of all hemophilia assets of Inspiration including OBI-1 and IB1001. Inspiration and Ipsen have collaborated with Cangene Corporation, which would acquire the global rights to Inspiration's hemophilia B product, IB1001 (recombinant FIX), and also Inspiration's rights to IB1007 (recombinant FVIIa) and IB1008 (recombinant FVIII) by paying over US$300 million. Prior to this sale, Inspiration and Ipsen have completed the sale process of the former’s OBI-1 (recombinant porcine FVIII) to Baxter International for over US$700 million. OBI-1 and IB1001 are the key products of Inspiration developed to offer safe and efficient recombinant therapies to treat hemophilia patients worldwide. With the completion of this sale process, all hemophilia assets would be globally commercialized by Baxter and Cangene.
Novozymes Biopharma and EpiVax Ink Research Agreement
Novozymes Biopharma, part of Denmark-based Novozymes A/S, has inked a research agreement with EpiVax, Inc., a biotechnology company based in Rhode Island, United States, for advancing therapies of autoimmune diseases. Under this agreement, the proprietary Tregitope (T regulatory epitopes) immune-modulating therapy of EpiVax used in type 1 diabetes treatment would be integrated with the Albufuse half-life extension platform of Novozymes. This integration of technologies would develop a safe and efficient technology platform to utilize Tregitopes for multiple autoimmunity, transplantation and allergy conditions. This integrated platform would offer enhanced disease control by improving the overall treatment efficiency. The companies would advance the next stage development of autoimmune diseases treatment.
Glenmark Pharmaceuticals SA Discovers and Initiates IND Studies for GBR 830
Glenmark Pharmaceuticals Limited India's wholly owned subsidiary, Switzerland-based Glenmark Pharmaceuticals SA, has discovered and initiated investigational new drug (IND) enabling studies of a new clinical development candidate, GBR 830, an antagonistic mAb targeting OX40. La Chaux-deFonds, Switzerland-based Glenmark Biologics Research Centre has discovered and developed GBR 830. At present, no anti-OX40 antibodies exist in the clinical development stage. GBR 830 offers potential in being the therapeutic choice for treatment of immune pathologies such as autoimmune diseases like rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). The discovery product line of the company would be enhanced by the antibody knowhow and production potencies of Glenmark Biologics Research Centre.
